Heat-labile enterotoxin, E coli clinical trials
Also written AD17002.
How each study uses heat-labile enterotoxin, E coli is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the heat-labile enterotoxin, E coli studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 4
Advagene Biopharma Co. Ltd. (4) · PATH (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Vermont (1)
Studies
Open first, then newest update. How each study uses heat-labile enterotoxin, E coli is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic AsthmaNot yet recruitingPhase 2Advagene Biopharma Co. Ltd.NCT07250594Written as AD17002
- Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy AdultsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06692907Written as dmLT
- Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic RhinitisCompletedPhase 1/2Advagene Biopharma Co. Ltd.NCT04088721Written as AD17002
- AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic AsthmaCompletedPhase 1/2Advagene Biopharma Co. Ltd.NCT05985694Written as AD17002
- Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19CompletedPhase 1/2Advagene Biopharma Co. Ltd.NCT05069610Written as AD17002
- Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)CompletedPhase 1PATHNCT03404674Written as dmLT
- Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) AdjuvantCompletedPhase 1University of VermontNCT03922061Written as dmLT
- Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in BangladeshCompletedPhase 1/2PATHNCT02531802Written as dmLT
Given beside what is tested · 2 — heat-labile enterotoxin, E coli is usual care or a partner of the new treatment
- A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in KenyaCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT04826094Written as dmLT
- Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in AdultsCompletedPhase 1/2PATHNCT01739231Written as dmLT
Codes
What other systems call heat-labile enterotoxin, E coli · ClinicalTrials.gg INT002856
- MeSH (NLM) C027538heat-labile enterotoxin, E coliConfirmed ClinicalTrials.gov, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C027538 | heat-labile enterotoxin, E coli | Confirmed ClinicalTrials.gov, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.